China NMPA Inspection - Jilin Huizhongkang Pharmaceutical Co., Ltd. - September 07, 2020

The Jilin Provincial Drug Administration, an authority operating under China's National Medical Products Administration (NMPA), issued an announcement on September 7, 2020, regarding the cancellation of a Cosmetics Production License. The announcement detailed the cessation of manufacturing authorization for Jilin Huizhongkang Pharmaceutical Co., Ltd., a company based in Xinli Village, Shaoguo Town, Nong'an County, Changchun City, Jilin Province. This regulatory action was not the result of an inspection or identified non-compliance, but rather stemmed from the company's voluntary application. In accordance with the "Cosmetics Production Licensing Work Specifications," the Jilin Provincial Drug Administration processed and approved the enterprise's request to cancel its existing license, identified as Jizhuang 20180007. Prior to this cancellation, Jilin Huizhongkang Pharmaceutical Co., Ltd. was licensed to produce a range of cosmetic items, including general liquid unit products such as skin care water, and various cream and lotion unit products for both skin care and cleansing purposes. As the cancellation was initiated by the company itself through a voluntary application, there were no specific violations or regulatory issues reported, and consequently, no corrective actions were mandated by the provincial drug administration. The announcement officially signifies the company's withdrawal from cosmetic production operations under the purview of the Chinese regulatory framework.